| 3/13/2009 | CV | Market Commentary: Johnson Controls, Bank of America, Nasdaq, GM gain with stocks; CV Therapeutics quiets, holds firm
|
| 3/12/2009 | CV | Gilead to assume $292 million in CV Therapeutics' convertible debt
|
| 3/12/2009 | CV | Market Commentary: CV Therapeutics higher, Gilead slips on merger news; Johnson Controls convertibles move upward
|
| 2/25/2009 | CV | CV Therapeutics reduces amount of convertibles outstanding by $107.3 million in 2008
|
| 1/27/2009 | CV | Market Commentary: CV Therapeutics jumps on bid; Bank of America, Citigroup gain amid rumors; Newmont launches deal
|
| 1/16/2009 | CV | CV Therapeutics retired more than $100 million of convertibles in 2008
|
| 11/6/2008 | CV | CV Therapeutics repurchases $14.9 million of its convertibles
|
| 7/31/2008 | CV | CV Therapeutics repurchases $53 million in convertible subordinated notes
|
| 4/16/2008 | CV | Market Commentary: Little moved amid stock gains; Countrywide, CV gain, Kinetic Concepts falls below par; Huntington prices
|
| 5/16/2007 | CV | Market Commentary: Bausch & Lomb gains on buyout; CV Therapeutics keeps rising; Countrywide, Micron launch giant deals
|
| 3/27/2007 | CV | Market Commentary: CV Therapeutics, AtheroGenics gain on data; Equinix higher, Kilroy quiet in gray
|
| 3/26/2007 | CV | Market Commentary: CV Therapeutics drops on downgrade; Freeport-McMoran leads new deals; Nortel, SL Green, Vornado slip
|
| 3/7/2007 | CV | Market Commentary: CV Therapeutics, Conseco fall with stocks; Barnes gains on debut; Cypress up, Developers quiet in gray
|
| 2/23/2007 | CV | Reaping lessons from Wild Oats: Market value-based make-whole feature caps protection, says Lehman
|
| 8/14/2006 | CV | Market Commentary: CV Therapeutics gets hit; Ford gains on upgrade; Calgon borrow uncertain; Tanger climbs further
|
| 5/23/2006 | CV | Market Commentary: Cameron debut hurt by premium; Global Crossing deal sees poor borrow; CBIZ prices offer within talk
|
| 5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
| 1/30/2006 | CV | Market Commentary: Omnicare converts plunge on raid news; new DRS issue slows down; GMAC bids lift GM
|
| 1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
| 1/19/2006 | CV | Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
|
| 7/22/2005 | CV | Market Commentary: Cheniere deal, earnings boost convertible market's energy names; biotech eases slightly
|
| 7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
| 7/13/2005 | CV | Market Commentary: Advanced Medical's new issue jumps, spurring overall market; Continental rebounds, Liberty Media mixed
|
| 7/13/2005 | BTCV | CV Therapeutics calls $79.65 million 4.75% convertibles
|
| 7/7/2005 | CV | Market Commentary: Biotechs up as convertibles find footing after early dip; airlines down; some oil and gas names extend gains
|
| 7/6/2005 | CV | Market Commentary: Cooper Cameron, Halliburton rise as oil prices surge; Schering-Plough eases, but LSI gains
|
| 7/1/2005 | CV | Market Commentary: Brocade convertibles lift on default notice; market activity quiets ahead of holiday weekend
|
| 7/1/2005 | BTCV | CV Therapeutics greenshoe exercised in full, raising 3.25% convertibles offer to $149.5 million
|
| 6/29/2005 | CV | New Issue: CV Therapeutics upsized $130 million convertibles yield 3.25%, up 25%
|
| 6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
| 6/27/2005 | CV | Market Commentary: Lear eases on layoffs; airlines dive on oil spike; Weatherford watched as put nears; CV, Impax deals eyed
|
| 6/23/2005 | CV | Market Commentary: Convertibles market trades mostly lower, but some energy issues climb with oil prices
|
| 6/22/2005 | CV | Market Commentary: CV Therapeutics, Evergreen Solar launch after quiet day; Reckson deal upsized, reoffered in thin trade
|
| 6/22/2005 | BTCV | CV Therapeutics to price $100 million convertibles talked at 3.25%-3.75%, up 20%-25%
|
| 6/22/2005 | BTCV | CV Therapeutics plans to buy back up to $79.6 million 4.75% convertibles with new deal proceeds
|
| 8/9/2004 | CV | CV Therapeutics buybacks of 4.75% convertibles now total $116.6 million
|
| 6/8/2004 | CV | CV Therapeutics greenshoe exercised, raising convertibles to $150 million
|
| 6/3/2004 | CV | Market Commentary: Beazer hangs around par; Phelps Dodge dividend crushes hedgers; CV Therapeutics up on drug news
|
| 5/14/2004 | CV | CV Therapeutics brings buybacks of 43/4% convertibles to $101.6 million
|
| 5/13/2004 | CV | New Issue: CV Therapeutics upsized $125 million convertible yields 2.75%, up 27.5%
|
| 5/13/2004 | CV | Market Commentary: CV Therapeutics, Pixelworks both trade below par out of gate; Tower Auto deal piques interest
|
| 5/12/2004 | CV | Market Commentary: CV Therapeutics bid at 100.375 in gray market; Pixelworks still; OSI Pharma, ImClone up sharply
|
| 5/11/2004 | CV | CV Therapeutics $100 million convertible talked at 23/4%-31/4%, up 25%-30%
|
| 5/11/2004 | CV | Market Commentary: Electronic Data Systems active on potential dividend cut and equity issuance
|
| 12/18/2003 | CV | Deutsche analyst: CV Therapeutics convertibles should fare well despite drug setback
|
| 10/17/2003 | CV | Market Commentary: XL holds up against stock slide on warning, boost to reserves; new Getronics euro issue zooms
|
| 6/13/2003 | CV | New Issue: CV Therapeutics $100 million convertibles yield 2.0%, up 34%
|
| 6/12/2003 | CV | CV Therapeutics $100 million convertibles talked to yield 1.5-2.0%, up 34-38%
|
| 6/12/2003 | CV | Market Commentary: Yield-grabbers reach for busted convertibles, distressed issues; new paper mixed in secondary
|
| 4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
| 11/14/2001 | CV | Market Commentary: Convertible market slows in flat session; CV Therapeutics soars
|
| 11/13/2001 | CV | Merrill Lynch says CV Therapeutics poised to pop, convert attractive for hedge or outright investors
|
